Medicosnext
Roche and Atea Pharmaceutical are collaborating to develop, manufacture, and distribute Atea’s investigational oral direct-acting antiviral AT-527, which acts by blocking the viral RNA polymerase enzyme needed for viral replication. It is currently undergoing phase 2 clinical trial for hospitalized patients with moderate COVID-19, with phase 3 clinical trial expected …
Read More »Roche /Atea Pharmaceuticals collaborate to develop oral COVID-19 treatment
